文献速递消化道肿瘤与早癌消化内镜

血液检测可提高拒绝结肠镜和粪便免疫化学检测者的结直肠癌筛查参与率:一项随机对照试验

Blood Test Increases Colorectal Cancer Screening in Persons Who Declined Colonoscopy and Fecal Immunochemical Test: A Randomized Controlled Trial.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-04-08

本研究纳入既往6个月内拒绝结肠镜和粪便免疫化学检测(FIT)的50-75岁筛查合格退伍军人,随机分为仅重新提供结肠镜/FIT(对照组)或额外提供septin 9血液检测作为二线选择(干预组)。完成随访的359人中,干预组任何筛查完成率17.1% vs 对照组9.6%(差异7.5%,P=0.035),但完整筛查策略完成率9.0% vs 14.9%(差异5.9%,P=0.084)未达统计学显著。

要点

  • 对拒绝结肠镜和FIT者额外提供血液检测,任何筛查完成率提高7.5%(17.1% vs 9.6%,P=0.035)。
  • 两组结肠镜和FIT的 uptake 相似,提供血液检测未降低一线筛查选项的 uptake。
  • 完整筛查策略完成率干预组14.9% vs 对照组9.0%(差异5.9%,P=0.084),未达统计学显著。

核心结论

  • 在既往拒绝结肠镜和FIT的个体中,提供血液检测作为二线选择使筛查完成率提高7.5%,且未降低一线筛查选项的 uptake;但完整筛查策略完成率未增加。
  • 作者认为血液检测是改善结直肠癌筛查的有前景的方法,但非侵入性检测阳性后及时完成结肠镜仍是一个挑战。

研究设计与样本

  • 随机对照试验,纳入既往6个月内拒绝结肠镜和FIT的50-75岁筛查合格退伍军人,随机分为仅重新提供结肠镜/FIT(对照组)或额外提供血液检测作为二线选择(干预组)。
  • 主要结局为6个月内完成任何筛查检测;次要结局为6个月内完成完整筛查策略,包括非侵入性检测阳性者完成结肠镜。
  • 完成随访的参与者共359人。

主要发现

  • 完成任何筛查:干预组17.1% vs 对照组9.6%(差异7.5%,P=0.035)。
  • 完整筛查策略完成:干预组14.9% vs 对照组9.0%(差异5.9%,P=0.084)。
  • 两组结肠镜和FIT的 uptake 相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The septin 9 blood test is indicated for colorectal cancer screening in individuals who decline first-line tests, but participation in this context is unclear. We conducted a randomized controlled trial to compare reoffering colonoscopy and fecal immunochemical test (FIT) alone versus also offering the blood test among individuals who declined colonoscopy and FIT. METHODS: Screen-eligible Veterans aged 50-75 years who declined colonoscopy and FIT within the previous 6 months were randomized to letter and telephone outreach to reoffer screening with colonoscopy/FIT only (control), or additionally offering the blood test as a second-line option (intervention). The primary outcome was completion of any screening test within 6 months. The secondary outcome was completion of a full screening strategy within 6 months, including colonoscopy for those with a positive noninvasive test. RESULTS: Of 359 participants who completed follow-up, 9.6% in the control group and 17.1% in the intervention group completed any screening (7.5% difference; P = .035). Uptake of colonoscopy and FIT was similar in the 2 groups. The full screening strategy was completed in 9.0% and 14.9% in the control and intervention groups, respectively (5.9% difference; P = .084). CONCLUSIONS: Among individuals who previously declined colonoscopy and FIT, offering a blood test as a secondary option increased screening by 7.5% without decreasing uptake of first-line screening options. However, completion of a full screening strategy did not increase. These findings indicate that a blood test is a promising method to improve colorectal cancer screening, but obtaining a timely colonoscopy after a positive noninvasive test remains a challenge (ClincialTrials.gov number, NCT03598166).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Liang PS, Zaman A, Kaminsky A, et al. Blood Test Increases Colorectal Cancer Screening in Persons Who Declined Colonoscopy and Fecal Immunochemical Test: A Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2023. PMID: 37037262. doi:10.1016/j.cgh.2023.03.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。